Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Schaeffer

Showing results (101-110 of 172) with videos related to

Pageof 18
Sort By:
Frontiers in Genetics|November 29, 2023
Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)Jannat Pervin, Mohammad Asad, Shaolong Cao, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White PaperDavid F Schaeffer, Jennifer Chan, Jason Morin, et al.
Cancer Control : Journal of the Moffitt Cancer Center|February 19, 2026
Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, CanadaAshley Paul, Shehara Mendis, Michael Diaz-Stewart, et al.
Cold Spring Harbor Molecular Case Studies|February 14, 2018
Molecular characterization of <i>ERBB2</i>-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive casesDaniel R Owen, Hui-Li Wong, Melika Bonakdar, et al.
The American Journal of Surgical Pathology|January 31, 2015
Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinomaKate O'Connor, Hector H Li-Chang, Steven E Kalloger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2020
Population-based Screening for <i>BRAF</i> <sup>V600E</sup> in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor PrognosisJenny E Chu, Benny Johnson, Laveniya Kugathasan, et al.
Cell Death & Disease|March 18, 2020
PRDM3 attenuates pancreatitis and pancreatic tumorigenesis by regulating inflammatory responseJie Ye, Anpei Huang, Haitao Wang, et al.
Human Pathology|April 29, 2014
ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohortsKimberly C Wiegand, Keiyan Sy, Steve E Kalloger, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 23, 2018
siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell GrowthShane P Duggan, Catherine Garry, Fiona M Behan, et al.
The Journal of Molecular Diagnostics : JMD|November 26, 2018
A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical SpecimensMiguel Alcaide, Matthew Cheung, Kevin Bushell, et al.
Pageof 18

Showing results (101-110 of 172) with videos related to

Sort By:
Pageof 18
Frontiers in Genetics|November 29, 2023
Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)Jannat Pervin, Mohammad Asad, Shaolong Cao, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White PaperDavid F Schaeffer, Jennifer Chan, Jason Morin, et al.
Cancer Control : Journal of the Moffitt Cancer Center|February 19, 2026
Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, CanadaAshley Paul, Shehara Mendis, Michael Diaz-Stewart, et al.
Cold Spring Harbor Molecular Case Studies|February 14, 2018
Molecular characterization of <i>ERBB2</i>-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive casesDaniel R Owen, Hui-Li Wong, Melika Bonakdar, et al.
The American Journal of Surgical Pathology|January 31, 2015
Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinomaKate O'Connor, Hector H Li-Chang, Steven E Kalloger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2020
Population-based Screening for <i>BRAF</i> <sup>V600E</sup> in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor PrognosisJenny E Chu, Benny Johnson, Laveniya Kugathasan, et al.
Cell Death & Disease|March 18, 2020
PRDM3 attenuates pancreatitis and pancreatic tumorigenesis by regulating inflammatory responseJie Ye, Anpei Huang, Haitao Wang, et al.
Human Pathology|April 29, 2014
ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohortsKimberly C Wiegand, Keiyan Sy, Steve E Kalloger, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 23, 2018
siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell GrowthShane P Duggan, Catherine Garry, Fiona M Behan, et al.
The Journal of Molecular Diagnostics : JMD|November 26, 2018
A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical SpecimensMiguel Alcaide, Matthew Cheung, Kevin Bushell, et al.
Pageof 18